A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

NCT05673928 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Solid Tumor
Brain Metastases

Interventions

DRUG: Trastuzumab emtansine
DRUG: Tucatinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]